Company intelligence / Profile preview

Celsius Therapeutics

Cambridge, Massachusetts, United Statescelsiustx.com ↗

Ownership: Private
Employees: ~35
Development stage: Other

Overview

Celsius Therapeutics advanced its lead candidate CEL383, an anti-TREM1 antibody, into a completed Phase 1 trial for IBD. The study evaluated safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers. No detailed results have been disclosed publicly as of the acquisition by AbbVie in June 2024.

Therapeutic areas: Gastroenterology
Modalities: Monoclonal antibodies (mAbs)Precision biologics (via single-cell genomics and machine learning)
Industry: Biotech

Partnerships

ServierUniversity of OxfordCleveland ClinicLMU University Hospital Munich

Beyond the preview

Go deeper on Celsius Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celsius Therapeutics.